Sugi Predict

Sugi Predict / Compounds / SCHEMBL382507

SCHEMBL382507

SCHEMBL382507

O=C(Oc1ccc([C](c2ccc(OC(=O)c3ccccc3)cc2)c2ccc(OC(=O)c3ccccc3)cc2)cc1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 1/20 0.72
▸ KMT2A Q03164 10/20 0.64
▸ MEN1 O00255 3/20 0.64
▸ MAPT P10636 4/20 0.62
▸ TDP1 Q9NUW8 2/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ PKM P14618 1/20 0.62
▸ RAB9A P51151 1/20 0.59
▸ ELANE P08246 1/20 0.55
▸ PRSS1 P07477 1/20 0.54
▸ ACR P10323 1/20 0.54
▸ TMPRSS15 P98073 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ HSD17B10 Q99714 1/20 0.53
▸ CASP3 P42574 1/20 0.53
▸ SENP7 Q9BQF6 1/20 0.53
▸ F2 P00734 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ NSD2 O96028 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578147 1.00 PARP10 (0.72) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL9663679 0.94 PARP10 (0.81) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL8205435 0.91 PARP10 (0.78) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL725405 0.91 PARP10 (0.77) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL28343302 0.91 PARP10 (0.62) PARP10KMT2AMEN1MAPTTDP1
Hydrochloric Acid SCHEMBL16050040 0.89 PARP10 (0.74) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL5676789 0.88 PARP10 (0.72) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL622771 0.88 PARP10 (0.72) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL10610456 0.88 PARP10 (0.72) PARP10KMT2AMEN1MAPTTDP1
SCHEMBL8206009 0.88 PARP10 (0.72) PARP10KMT2AMEN1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121719-A2 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS Alios Biopharma, Inc. (US) 2009-11-25 — — EP claimed
WO-2009086192-A1 BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO claimed
WO-2009086201-A1 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS ALIOS BIOPHARMA, INC. (US) 2009-07-09 — — WO claimed
WO-2008095040-A2 2-5A DERIVATIVES AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI-PARASITIC AGENTS ALIOS BIOPHARMA, INC. (US) 2008-08-07 — — WO claimed
US-20040142946-A1 Modified nucleosides and nucleotides and use thereof CHATTOPADHYAYA JYOTI (SE) 2004-07-22 — — US claimed
EP-1332150-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF Chattopadhyaya, Jyoti (SE) 2003-08-06 — — EP claimed
WO-2002038578-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF CHATTOPADHYAYA JYOTI (SE) 2002-05-16 — — WO claimed
US-6239220-B1 Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis ISIS PHARMACEUTICALS, INC. 2001-05-29 — — US claimed
US-6124484-A Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis ISIS PHARMACEUTICALS, INC. (US) 2000-09-26 — — US claimed
US-5721350-A Deuterated nucleosides CHATTOPADHYAYA JYOTI (SE) 1998-02-24 — — US claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 — — WO claimed
US-20240238321-A1 MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF SYNTHENA AG (CH) 2024-07-18 — — US disclosed
US-20240239974-A1 RESIN COMPOSITION, PREPREG USING SAME, FILM PROVIDED WITH RESIN, METAL FOIL PROVIDED WITH RESIN, METAL-CLAD LAMINATE, AND WIRING BOARD PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2024-07-18 — — US disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 — — WO disclosed
US-20240229026-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2024-07-11 — — US disclosed
US-6124484-A Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis ISIS PHARMACEUTICALS, INC. (US) 2000-09-26 — — US disclosed
US-6096907-A REDUCING A 7-HYDROXY-4-CHROMANONE OR DERIVATIVE WITH ZINC AND AN ACID BASF AKTIENGESELLSCAHFT (DE) 2000-08-01 — — US disclosed
EP-0989126-A1 Process for the production of chromanol derivatives BASF AKTIENGESELLSCHAFT (DE) 2000-03-29 — — EP disclosed
WO-2000004062-A1 RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2000-01-27 — — WO disclosed
US-5639867-A TTTr as protective group in nucleotide synthesis CIBA GEIGY CORPORATION (US) 1997-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142946-A1 Modified nucleosides and nucleotides and use thereof RNASEH1, RNASEL, NSUN2 PARP10 1511/4885KMT2A 1336/4885MEN1 4771/4885
US-20240229026-A1 CHIRAL CONTROL RNGTT, POLI, NSUN3 PARP10 2526/4885KMT2A 2211/4885MEN1 2026/4885
US-20240238321-A1 MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF MTPN, UTRN, DCTD PARP10 1081/4885KMT2A 2603/4885MEN1 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.